Aditxt Inc. Subsidiary Pearsanta Engages Spartan Capital for Planned IPO to Advance Cancer Detection
July 29th, 2025 3:35 PM
By: Newsworthy Staff
Aditxt Inc.'s subsidiary Pearsanta has appointed Spartan Capital Securities as the lead underwriter for its upcoming IPO, aiming to fund the commercialization of its early cancer and disease detection technologies.
Aditxt Inc. (NASDAQ: ADTX), a platform dedicated to accelerating health innovations, has announced that its subsidiary Pearsanta, Inc. has selected Spartan Capital Securities, LLC as the lead underwriter for its planned Initial Public Offering (IPO). This strategic move is designed to facilitate the clinical validation and broader market introduction of Pearsanta's innovative early detection tests for cancer and other diseases, leveraging its Mitomic mitochondrial DNA platform and a CLIA-certified, CAP-accredited laboratory infrastructure.
According to Aditxt CEO Amro Albanna, the IPO is a critical component of the company's Acquire, Build, and Capitalize strategy, which aims to enhance Pearsanta's ability to reach more markets and provide life-saving diagnostics through early detection. This initiative underscores Aditxt's commitment to fostering health innovations that address significant societal challenges.
For further details on the announcement, visit https://ibn.fm/npyvx.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
